Olav Engebraaten

Olav Engebraaten

UNVERIFIED PROFILE

Are you Olav Engebraaten?   Register this Author

Register author
Olav Engebraaten

Olav Engebraaten

Publications by authors named "Olav Engebraaten"

Are you Olav Engebraaten?   Register this Author

43Publications

549Reads

26Profile Views

Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients.

Acta Oncol 2019 Dec 26:1-6. Epub 2019 Dec 26.

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1704864DOI Listing
December 2019

Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients.

J Proteome Res 2019 Oct 16;18(10):3649-3660. Epub 2019 Sep 16.

Department of Oncology , Oslo University Hospital , 0424 Oslo , Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jproteome.9b00316DOI Listing
October 2019

Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft.

J Control Release 2019 01 4;293:183-192. Epub 2018 Dec 4.

Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Pharmacy, University of Tromsø, Tromsø, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2018.11.029DOI Listing
January 2019

Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment.

Cancer Lett 2018 12 18;439:1-13. Epub 2018 Sep 18.

Department of Tumor Biology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2018.09.023DOI Listing
December 2018

Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.

Mol Oncol 2017 10 24;11(10):1361-1379. Epub 2017 Jul 24.

NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623820PMC
October 2017

Fatigue During and After Breast Cancer Therapy-A Prospective Study.

J Pain Symptom Manage 2017 03 29;53(3):551-560. Epub 2016 Dec 29.

National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2016.09.011DOI Listing
March 2017

Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft.

PLoS One 2014 24;9(11):e113278. Epub 2014 Nov 24.

Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Cancer Stem Cell Innovation Centre, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113278PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242648PMC
July 2015

Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.

J Magn Reson Imaging 2014 Dec 27;40(6):1382-91. Epub 2014 Jan 27.

Department of Radiation Biology Institute of Cancer Research, Oslo University Hospital, Norway; Faculty of Medicine, University of Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.24502DOI Listing
December 2014

Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Clin Cancer Res 2014 Jan 5;20(2):404-12. Epub 2013 Nov 5.

Authors' Affiliations: Departments of Tumor Biology and Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital; Department of Oncology, Oslo University Hospital, Ullevaal and Institute of Clinical Medicine, University of Oslo, Oslo; Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; and Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/01/
Web Search
http://clincancerres.aacrjournals.org/content/early/2013/11/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326070PMC
January 2014

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

J Magn Reson Imaging 2013 Nov 21;38(5):1043-53. Epub 2013 Mar 21.

MI Lab, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.24079DOI Listing
November 2013

Triple-negative breast cancer and the need for new therapeutic targets.

Am J Pathol 2013 Oct 3;183(4):1064-1074. Epub 2013 Aug 3.

K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2013.05.033DOI Listing
October 2013

Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

Mol Oncol 2013 Feb 23;7(1):130-42. Epub 2012 Oct 23.

Department of Genetics, Institute for Cancer Research, Division for Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Norwegian Radium Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2012.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528408PMC
February 2013

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.

Mol Oncol 2012 Aug 31;6(4):418-27. Epub 2012 Mar 31.

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Pb 4953 Nydalen, 0424 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2012.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528356PMC
August 2012

In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.

J Magn Reson Imaging 2012 May 14;35(5):1098-107. Epub 2011 Dec 14.

MI Lab and Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.23507DOI Listing
May 2012

Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Mol Oncol 2011 Jun 23;5(3):224-41. Epub 2011 Apr 23.

Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2011.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528296PMC
June 2011

Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins.

Anticancer Res 2009 Jan;29(1):131-7

Department of Tumour Biology, Institute for Cancer Research, University of Oslo, Faculty Division, The Norwegian Radium Hospital, Montebello, Oslo, Norway.

View Article

Download full-text PDF

Source
January 2009

Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.

J Gene Med 2007 Jun;9(6):440-51

Department of Tumor Biology, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgm.1036DOI Listing
June 2007

Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines.

Cancer Biol Ther 2006 Nov 19;5(11):1511-20. Epub 2006 Nov 19.

Department of Tumor Biology, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.11.3301DOI Listing
November 2006

Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus.

J Gene Med 2006 Jun;8(6):707-18

Department of Tumor Biology, Rikshospitalet-Radiumhospitalet Health Enterprise, Montebello, N-0310 Oslo, Norway.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jgm.902
Publisher Site
http://dx.doi.org/10.1002/jgm.902DOI Listing
June 2006

Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells.

Exp Cell Res 2004 Mar;294(1):130-9

Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, 0310 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2003.10.013DOI Listing
March 2004

Expression of extracellular matrix components in a highly infiltrative in vivo glioma model.

Acta Neuropathol 2003 Jan 1;105(1):49-57. Epub 2002 Nov 1.

Department of Anatomy and Cell Biology, University of Bergen, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-002-0610-0DOI Listing
January 2003

Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals.

Int J Cancer 2002 Feb;97(6):846-52

Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.10137DOI Listing
February 2002

Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells.

Int J Cancer 2002 Jan;97(1):28-33

Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.1564DOI Listing
January 2002